...Good morning. I'm Pete Salzmann, Chief Executive Officer of Immunovant, and I'm excited to welcome you to Immunovant's R&D Day where we have an opportunity to dive deeper into our asset, our program and our opportunity. We'll be making some forward-looking statements over the course of the day, and investors should carefully read this slide available on our website and in the 8-K we filed this morning. Before we jump in, I'd like to cover some housekeeping for how we'll handle Q&A from the audience. We're very interested to address any questions that you may have, and so throughout the day, please use the chat function to submit your questions, which we will address at the end of the program. If you'd like to submit them anonymously, that's okay too. I'm going to kick things off today with a brief company and asset overview, after which we'll cover information related to our 3 announced indications. As most of you know, Immunovant was established with a dedicated purpose: To advance the...
